^
    1d
    FAM83A acts as an amplifier for lipogenic signaling to facilitate the pathogenesis of metabolic dysfunction-associated steatohepatitis. (PubMed, Metabolism)
    FAM83A promotes MASH pathogenesis by interacting with RAF1 to activate ERK signaling, thereby stimulating fatty acid and cholesterol biosynthesis. Targeting this axis may offer therapeutic potential for MASH and metabolic dyslipidemia.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    sorafenib • PD98059
    1d
    Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance). (PubMed, ESMO Open)
    OS can be accurately predicted in patients with HCC receiving sorafenib by combining certain radiomics features with clinical metadata, centered primarily on baseline characteristics.
    Journal
    |
    AFP (Alpha-fetoprotein)
    |
    sorafenib • doxorubicin hydrochloride
    1d
    CaboTx: Cabozantinib to Treat Recurrent Liver Cancer Post Transplant (clinicaltrials.gov)
    P2, N=20, Recruiting, University Health Network, Toronto | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Aug 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Cabometyx (cabozantinib tablet)
    1d
    Novel crystalline solid dispersions to improve the oral bioavailability and anti-liver cancer effect of Sorafenib. (PubMed, Drug Deliv Transl Res)
    Collectively, our findings underscore the pivotal role of Sh/TgE in modulating drug particle size within CSD matrices through distinct mechanisms. Furthermore, our study underscores the potential of P188-mediated CSD formulations in augmenting the dissolution rate and bioavailability of poorly soluble drugs by minimizing drug particle size and sustaining drug supersaturation, thereby enhancing the efficacy of sorafenib in treating liver cancer.
    Journal
    |
    CD34 (CD34 molecule) • GPX4 (Glutathione Peroxidase 4) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    sorafenib
    2d
    Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer (clinicaltrials.gov)
    P2, N=29, Recruiting, University of Arizona | Trial completion date: Oct 2025 --> Jan 2026 | Trial primary completion date: Oct 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet)
    2d
    GANCE: Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, First Affiliated Hospital of Zhejiang University
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • cytarabine • Xospata (gilteritinib) • azacitidine
    2d
    Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body (clinicaltrials.gov)
    P2/3, N=437, Active, not recruiting, Children's Oncology Group | Recruiting --> Active, not recruiting | Initiation date: Jul 2026 --> Nov 2025
    Enrollment closed • Trial initiation date
    |
    doxorubicin hydrochloride • cyclophosphamide • Stivarga (regorafenib) • ifosfamide • etoposide IV • irinotecan • vincristine
    2d
    AAML1831: A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (clinicaltrials.gov)
    P3, N=1186, Recruiting, Children's Oncology Group | Trial completion date: Sep 2027 --> Jun 2029 | Trial primary completion date: Sep 2027 --> Jun 2029
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    Xospata (gilteritinib) • etoposide IV • methotrexate • Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • mitoxantrone • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Starasid (cytarabine ocfosfate) • dexrazoxane
    3d
    Chronic stress-induced ANPEP drives liver cancer progression by increasing glutathione synthesis and inhibiting ferroptosis. (PubMed, J Clin Invest)
    The combination of ANPEP silencing and sorafenib treatment showed a synergistic effect in inhibiting liver cancer progression. Finally, clinical data and mouse models demonstrated that chronic stress drove liver tumor progression via ANPEP-regulated SLC3A2. These findings reveal unanticipated communication between chronic stress and metabolic reprogramming during liver cancer progression, providing potential therapeutic implications for liver cancer.
    Journal
    |
    SLC3A2 (Solute Carrier Family 3 Member 2) • ANPEP (Alanyl Aminopeptidase, Membrane)
    |
    sorafenib
    3d
    Proteoglycan-4 potentiates the antitumor efficacy of regorafenib in an orthotopic model of hepatocellular carcinoma. (PubMed, J Exp Clin Cancer Res)
    PRG4 demonstrated antitumor activities in vivo and shows promise as an adjuvant to enhance therapeutic interventions in HCC.
    Journal
    |
    PRG4 (Proteoglycan 4)
    |
    Stivarga (regorafenib)
    3d
    Efficacy and safety with aumolertinib plus anlotinib for untreated EGFR-mutant NSCLC with brain metastases. (PubMed, NPJ Precis Oncol)
    Aumolertinib plus anlotinib was effective and well-tolerated as first-line therapy in EGFR-mutant NSCLC patients with BMs. Trial Registration: ClinicalTrials.gov(identifier NCT04978753, registered July 20, 2021).
    Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53)
    |
    TP53 mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • TP53 wild-type • EGFR positive
    |
    Focus V (anlotinib) • Ameile (aumolertinib)
    4d
    Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma (clinicaltrials.gov)
    P2, N=20, Recruiting, The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Focus V (anlotinib) • Tevimbra (tislelizumab-jsgr)